2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
2043
Neoplasms
1458
Carcinoma, Non-Small-Cell Lung
1360
Prostatic Neoplasms
1104
Multiple Myeloma
870
Leukemia, Myeloid, Acute
767
Colorectal Neoplasms
710
Neoplasm Metastasis
702
Lung Neoplasms
696
Melanoma
683
Lymphoma
665
Leukemia
595
Lymphoma, Non-Hodgkin
592
Leukemia, Lymphocytic, Chronic, B-Cell
535
Ovarian Neoplasms
530
Pancreatic Neoplasms
500
Precursor Cell Lymphoblastic Leukemia-Lymphoma
483
Recurrence
474
Myelodysplastic Syndromes
424
Lymphoma, Follicular
418
Carcinoma, Renal Cell
410
Head and Neck Neoplasms
407
Glioblastoma
380
Lymphoma, Large B-Cell, Diffuse
379
Brain Neoplasms
374
Hodgkin Disease
354
Carcinoma, Hepatocellular
332
Squamous Cell Carcinoma of Head and Neck
326
Lymphoma, Mantle-Cell
306
Sarcoma
286
Interventions
enzalutamide
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Biochemically Recurrent Prostate Cancer
×
Clear all
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts